Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019;58(1):101-104.
doi: 10.2169/internalmedicine.0927-18. Epub 2019 Jan 1.

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib

Tomoyuki Ikeuchi  1 , Hirokazu Tokuyasu  1 , Soichiro Ishikawa  1
Affiliations
Case Reports

Successful Treatment of Lung Adenocarcinoma with Epidermal Growth Factor Receptor Compound Mutations Involving Exon 19 Deletion and Exon 20 Insertion by Afatinib

Tomoyuki Ikeuchi et al. Intern Med. 2019.

Abstract

A 70-year-old woman was referred to our hospital after a nodular shadow was noted on chest X-ray. Chest computed tomography showed a pulmonary mass in the right upper lobe, and brain magnetic resonance imaging revealed a right-sided frontal lobe tumor. A histological examination of a transbronchial lung biopsy specimen revealed adenocarcinoma with epidermal growth factor receptor mutations involving both exon 19 deletion and exon 20 insertion. After stereotactic radiotherapy for brain metastasis, the patient was treated with afatinib, which resulted in a complete response. We observed a case in which a patient had non-small cell lung cancer with compound EGFR mutations involving both exon 19 deletion and exon 20 insertion mutations that responded well to afatinib therapy.

Keywords: afatinib; complete response; compound mutation; exon 19 deletion; exon 20 insertion.

PubMed Disclaimer

Conflict of interest statement

The authors state that they have no Conflict of Interest (COI).

Figures

Figure 1.
Figure 1.
Computed tomography showing a pulmonary mass in the right upper lobe.
Figure 2.
Figure 2.
Brain magnetic resonance imaging showing a 1-cm right-sided frontal lobe tumor (arrow).
Figure 3.
Figure 3.
Chest computed tomography showing the disappearance of the pulmonary lung tumor two months after starting treatment with afatinib.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMap II). Am J Cancer Res 5: 2892-2911, 2015. - PMC - PubMed
    1. Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci 107: 1179-1186, 2016. - PMC - PubMed
    1. Yang JC, Sequist LV, Greater SL, et al. . Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol 16: 830-838, 2015. - PubMed
    1. Kim EY, Cho EN, Park HS, et al. . Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther 17: 237-245, 2016. - PMC - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009. - PubMed

Publication types

MeSH terms